Cover Image
市場調查報告書

被套細胞淋巴瘤 (非何杰金氏淋巴瘤的亞型):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析

NHL: Mantle cell lymphoma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365191
出版日期 內容資訊 英文 214 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
被套細胞淋巴瘤 (非何杰金氏淋巴瘤的亞型):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析 NHL: Mantle cell lymphoma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 214 Pages
簡介

從2016年到2025年的被套細胞淋巴瘤 (MCL) 治療藥的市場,預計隨著發病數的擴大與Imbruvica、Revlimid等高額的治療藥的利用擴大等要素而成長。

本報告提供非何杰金氏淋巴瘤亞型的被套細胞淋巴瘤 (MCL)的治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:被套細胞淋巴瘤

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Imbruvica (ibrutinib)
  • Revlimid (lenalidomide)
  • Rituxan (Rituximab)
  • Torisel (temsirolimus)
  • Velcade (bortezomib)
  • 一次調查技術

治療方法:被套細胞淋巴瘤

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢:侷限期 (I/II)
  • 處方趨勢:Bulky期 (II/III/IV)

流行病學:被套細胞淋巴瘤

  • 摘要整理
  • 疾病的背景
  • 資訊來源、分析方法
  • 預測:非何杰金氏淋巴瘤全體
  • 預測:非何杰金氏淋巴瘤亞型 (DLBCL、FL、MCL)
  • 流行病學者的見解
  • 優勢、規定

上市藥:被套細胞淋巴瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Imbruvica
  • 產品簡介:Revlimid
  • 產品簡介:Rituxan
  • 產品簡介:Torisel
  • 產品簡介:Treanda
  • 產品簡介:Velcade

開發平台:被套細胞淋巴瘤

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (開發後期):Darzalex
  • 產品簡介 (開發後期):Gazyva
  • 產品簡介 (開發後期):KTE-C19
  • 產品簡介 (開發後期):Kyprolis

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13367

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016-25.

This report addresses the following questions:

  • What will be driving the growth of the MCL market during 2016-25?
  • Which markets will experience the biggest growth?
  • Which branded therapies will have the largest impact on the MCL market?
  • What is the overall market potential for Imbruvica and Revlimid?
  • When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

TABLE OF CONTENTS

FORECAST: MANTLE CELL LYMPHOMA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Imbruvica (ibrutinib)
  • 5. Revlimid (lenalidomide)
  • 6. Rituxan (rituximab)
  • 7. Torisel (temsirolimus)
  • 8. Velcade (bortezomib)
  • 9. Primary Research Methodology

TREATMENT: MANTLE CELL LYMPHOMA

  • 10. Executive Summary
  • 11. Primary Research Methodology
  • 12. Disease Definition and Diagnosis
  • 13. Patient Segmentation
  • 14. Country Treatment Trees
  • 15. Current Treatment Options
  • 16. Prescribing Trends: Localized Stage (I/II)
  • 17. Prescribing Trends: Bulky Stage (II/III/IV)

EPIDEMIOLOGY: MANTLE CELL LYMPHOMA

  • 18. Executive Summary
  • 19. Disease Background
  • 20. Sources and Methodology
  • 21. Forecast: NHL Overall
  • 22. Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL)
  • 23. Epidemiologist Insight
  • 24. Strengths and Limitations

MARKETED DRUGS: MANTLE CELL LYMPHOMA

  • 25. Executive Summary
  • 26. Product Overview
  • 27. Product profile: Imbruvica
  • 28. Product profile: Revlimid
  • 29. Product profile: Rituxan
  • 30. Product profile: Torisel
  • 31. Product profile: Treanda
  • 32. Product profile: Velcade

PIPELINE: MANTLE CELL LYMPHOMA

  • 33. Executive Summary
  • 34. Clinical Pipeline Overview.
  • 35. Product profile (late stage): Darzalex.
  • 36. Product profile (late stage): Gazyva
  • 37. Product profile (late stage): KTE-C19
  • 38. Product profile (late stage): Kyprolis
Back to Top